Wegovy subscription: what ongoing treatment actually looks like in the UK

Step 1: the first prescription sets the clinical baseline

Before any Wegovy pen is dispensed, a prescriber must assess whether the medicine is appropriate for you. That means checking your BMI, your medical history, any medicines you take, and whether there are contraindications, a history of pancreatitis, for instance, or medullary thyroid carcinoma, are reasons a prescriber would not proceed. This is not bureaucracy for its own sake. It is the legal and clinical gate that makes the whole thing safe. The Wegovy overview on our site sets out the licensed eligibility criteria in full if you want to read them before you consult.

At this stage you will also discuss which dose you are starting on. Treatment begins at 0.25mg, a tolerability dose whose job is to let your system adjust, not to drive significant weight loss on its own. The titration schedule, moving through 0.5mg, 1.0mg, 1.7mg and up to 2.4mg (with a newer 7.2mg dose now also approved by the MHRA), is managed by your prescriber in roughly monthly steps. What Wegovy involves as a treatment is worth understanding before that first conversation, so you can ask the right questions.

Step 2: every repeat order is a clinical re-review, not an auto-renewal

This is the part that surprises people most, and where the misconception about subscriptions does the most damage. A common assumption is that once you are approved and on treatment, the pharmacy just keeps sending pens until you cancel. That would not be legal for a prescription-only medicine, and it would not be safe either. Dose increases, changes in your health, new medicines, pregnancy, any of these can affect whether continuing is appropriate, and a prescriber needs to know.

At nume, there are no auto-renewals. Every repeat order goes through a same-day clinical review by a GPhC-registered prescriber before anything is dispatched. That review checks your current weight, progress, and any side effects or concerns you have raised. If you are considering Wegovy without an ongoing plan, or simply want to understand what flexibility looks like, that page is a useful read alongside this one. For context on how Wegovy pricing works in the UK private market, including what a legitimate price includes, that page gives an honest picture.

Step 3: managing side effects and knowing when to pause

GLP-1 medicines like semaglutide have a well-established side-effect profile, and being prepared for it makes treatment easier to stick with. Nausea is the most commonly reported effect, particularly in the first few weeks or after a dose increase. Diarrhoea, constipation, indigestion and fatigue are also reported. Most people find these settle as the body adjusts, but some need a slower titration schedule, which is exactly the kind of decision a prescriber should make with you, not one you should navigate alone. The NHS semaglutide page has a clear summary of what to watch for and which symptoms need prompt medical attention.

On that point: severe, persistent stomach pain that spreads to your back (with or without vomiting) should prompt urgent medical help, as it can be a sign of pancreatitis. The MHRA flagged this risk in a formal Drug Safety Update and it is worth knowing before you start. Any suspected side effects can be reported directly through the Yellow Card scheme. Your prescriber should also know if you are planning surgery, as anaesthetists need to be told about GLP-1 treatment in advance. Women using oral contraceptives starting tirzepatide should add a non-oral method for the first four weeks; for semaglutide, NHS guidance notes no equivalent evidence of reduced pill effectiveness, but this is worth confirming with your prescriber.

Step 4: when and how treatment ends

NICE's guidance on semaglutide (Wegovy) recommends that NHS use is time-limited to a maximum of two years, within a specialist service. Private treatment does not carry the same automatic time cap, but that does not mean indefinite treatment is the right answer for everyone. If weight loss stalls (specifically, less than 5% reduction after six months at the highest tolerated dose) continuing is unlikely to be the right clinical choice, and a good prescriber will say so. That is a feature of proper clinical oversight, not a failure.

People sometimes ask whether they can simply stop. You can, but a managed exit is better than an abrupt one. Weight can return after stopping, and understanding what lifestyle and dietary support to build around treatment matters. The weight loss treatment overview covers what wraparound support looks like alongside medication. If you want to explore what other licensed options exist, alternatives to Wegovy are covered separately. And if you have a question that the main FAQs page does not answer, our team is reachable through the contact page any day of the week.

When you are ready to talk through whether Wegovy is right for you, our free consultation puts your answers in front of a qualified prescriber the same day.